Companies Dominating the Vertebrobasilar Artery Syndrome Treatment Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Boehringer Ingelheim International GmbH
- Johnson & Johnson Services, Inc.
- Baxter International, Inc.
- Novartis AG
- Sanofi-aventis Groupe
- AbbVie Inc.
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of vertebrobasilar artery syndrome treatment is estimated at USD 48.63 billion.
The vertebrobasilar artery syndrome treatment market size was valued at USD 46.96 billion in 2024 and is likely to cross USD 62.31 billion by 2037, registering more than 2.2% CAGR during the forecast period i.e., between 2025-2037. The increasing spending in the field of protein chemistry, immunology, molecular biology, biochemistry, and microbiology will boost the market growth.
Asia Pacific industry is anticipated to dominate majority revenue share of 35% by 2037, on the back of emergent healthcare infrastructure and improvement in medical facilities in developing nations, such as India, China, Bangladesh, Singapore, and Indonesia, among others.
The major players in the market are Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Baxter International, Inc., Novartis AG, Sanofi-aventis Groupe, AbbVie Inc., Pfizer Inc.
